Neil Tween

Neil is Chief Financial Officer of Owlstone Medical, a company focussed on early detection and precision medicine. Owlstone Medical is the global leaders in Breath Biopsy ®, headquartered in Cambridge, UK and backed by global VC groups, with its lead asset focussing on the early detection of lung cancer. Neil is responsible for the finance and legal functions as well as Board and investor-level reporting, legal, compliance and other operational matters.

Previously Neil was VP of Finance at GW Pharmaceuticals, NASDAQ-listed biotechnology company based in the UK and U.S. GW was a global leader in discovering, developing, manufacturing and commercializing novel, regulatory approved therapeutics from its proprietary cannabinoid product platform to address a broad range of diseases. The company’s lead product, Epidiolex® (cannabidiol) oral solution, is approved in patients one-year and older for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome and Tuberous Sclerosis Complex (TSC), all of which are rare diseases characterized by severe early-onset epilepsy. Epidiolex was the first plant-derived cannabinoid medicine ever approved by the U.S. Food and Drug Administration (FDA). Neil was involved in many cross-functional initiatives, including global supply chain execution, FDA submissions and regulatory expansion into Europe.